In contrast to matrix metalloproteinases, serum adiponectin concentrations increase after radioiodine treatment of thyrotoxicosis
Open Access
- 1 January 2012
- journal article
- Published by Springer Nature in Thyroid Research
- Vol. 5 (1) , 12
Abstract
Matrix metalloproteinases (MMPs), together with their tissue inhibitors (TIMPs), remodel extracellular matrix under physiological and pathological conditions and are implicated in pathogenesis of cardiovascular diseases, cancer and in chronic inflammation. We have endeavoured to assess whether concentrations of MMPs, TIMPs, and anti-inflammatory adiponectin are altered by pharmacological treatment of acute thyrotoxicosis or by radioiodine therapy (RIT).Keywords
This publication has 29 references indexed in Scilit:
- Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese maleMedical Oncology, 2012
- The Effect of Thyroid Disorders on Lipid Levels and MetabolismMedical Clinics of North America, 2012
- Thyroid Hormone and the Cardiovascular SystemMedical Clinics of North America, 2012
- Hyperthyroidism-Associated Insulin Resistance Is Not Mediated by Adiponectin LevelsJournal of Thyroid Research, 2011
- Multiphasic roles for matrix metalloproteinases after strokeCurrent Opinion in Pharmacology, 2008
- Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular diseaseBiochemical Pharmacology, 2008
- Metalloproteinases and Vulnerable Atherosclerotic PlaquesTrends in Cardiovascular Medicine, 2007
- Cardiac Dysrhythmias and Thyroid Dysfunction - The Hidden Menace?The Journal of Clinical Endocrinology & Metabolism, 2002
- Cancer Mortality Following Treatment for Adult HyperthyroidismJAMA, 1998
- Radioiodine treatment of juvenile Graves diseaseExperimental and Clinical Endocrinology & Diabetes, 1997